Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.
We have analyzed the sensitivity of 14 human medulloblastoma- and glioma-derived cell lines to the clinically used methylating agents temozolomide and streptozotocin. The cell lines responded similarly to these agents, displaying a 3-fold range in cytotoxicity, assessed as the 10% survival dose (LD10). The contribution of O6-methylguanine-DNA methyltransferase (MGMT) to resistance, measured as reduction in the LD10 by O6-benzylguanine (O6-BG), varied among the lines by 1 order of magnitude for both agents. However, in all MGMT-expressing lines, O6-BG eliminated a threshold dose that accounted for up to one-half of the LD10. The effect of O6-BG on the rate of killing varied 13-fold for temozolomide and 14-fold for streptozotocin. Some lines displayed two subpopulations with different rates of killing, with one subpopulation that comprised 20-60% of cells showing essentially no dependence of the rate of killing on MGMT. O6-BG increased the range of the LD10 for both agents. The persistent, heightened variability in cytotoxicity in the absence of MGMT, the lack of correlation between MGMT content of the lines and cytoxicity (LD10), and the lack of correlation between MGMT content and the contribution of MGMT to resistance (O6-BG-mediated reduction of the LD10) reflect the operation of resistance mechanisms other than MGMT. We also analyzed sensitivity to methyl methanesulfonate, observing little dependence of resistance on MGMT and persistent variability in cytotoxicity in the presence of O6-BG. We discuss the implications for clinical use of methylators and O6-BG.
Bobola
M S
MS
Departments of Neurosurgery and Pathology, University of Washington, Seattle, Washington 98195, USA.
Tseng
S H
SH
Blank
A
A
Berger
M S
MS
Silber
J R
JR
D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D006147:Guanine / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D008741:Methyl Methanesulfonate / Q000494:pharmacology; D008745:Methylation; D008769:Methylnitronitrosoguanidine / Q000494:pharmacology; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000032:analysis / Q000502:physiology*; D013311:Streptozocin / Q000494:pharmacology*; D000077204:Temozolomide; D014407:Tumor Cells, Cultured
D018906:Antineoplastic Agents, Alkylating; C064976:O(6)-benzylguanine; D008769:Methylnitronitrosoguanidine; D013311:Streptozocin; D006147:Guanine; D003606:Dacarbazine; D008741:Methyl Methanesulfonate; D019853:O(6)-Methylguanine-DNA Methyltransferase; D000077204:Temozolomide